Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting available at Active Biotech’s website

Lund, September 13 2023 – Active Biotech (NASDAQ Stockholm:ACTI) announces today that data from the recently completed phase I study with the eye drop formulation of laquinimod, a small molecule immunomodulator in development for non-infectious uveitis, together with results from the intraocular biodistribution study of laquinimod eye drops in rabbit, are now available on the company website.

The data were presented in a poster session at the International Ocular Inflammation Society (IOIS) 2023 Meeting in Berlin.

The results presented included safety and tolerability in the phase I randomized, placebo-controlled study with laquinimod eye drops in healthy subjects conducted at the Medical University of Vienna, Department of Clinical Pharmacology. The clinical study (NCT05187403) included 54 healthy subjects who received single doses or multiple doses of laquinimod eye drops in one eye and placebo in the other eye. Laquinimod was demonstrated to be safe and tolerable; no serious adverse events were reported, and ocular assessments did not reveal any tolerability concerns.

In the ocular biodistribution study in rabbit, laquinimod was detected in the cornea and retina/choroid of the rabbit eye following administration of laquinimod eye drops.

A clinical ocular biodistribution study of the eye drop formulation will be conducted at the Byers Eye Institute, Stanford University (Palo Alto, California, USA) with the Principal Investigator Quan Dong Nguyen, MD, MSc, Professor of Ophthalmology, Medicine, and Pediatrics, Stanford University School of Medicine.

Read the poster here.